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Abstract: A minority of patients presenting to hospital with COVID-19 have bacterial co-infection.
Procalcitonin testing may help identify patients for whom antibiotics should be prescribed or with-
held. This study describes the use of procalcitonin in English and Welsh hospitals during the first
wave of the COVID-19 pandemic. A web-based survey of antimicrobial leads gathered data about the
use of procalcitonin testing. Responses were received from 148/151 (98%) eligible hospitals. During
the first wave of the COVID-19 pandemic, there was widespread introduction and expansion of
PCT use in NHS hospitals. The number of hospitals using PCT in emergency/acute admissions rose
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from 17 (11%) to 74/146 (50.7%) and use in Intensive Care Units (ICU) increased from 70 (47.6%) to
124/147 (84.4%). This increase happened predominantly in March and April 2020, preceding NICE
guidance. Approximately half of hospitals used PCT as a single test to guide decisions to discontinue
antibiotics and half used repeated measurements. There was marked variation in the thresholds used
for empiric antibiotic cessation and guidance about interpretation of values. Procalcitonin testing has
been widely adopted in the NHS during the COVID-19 pandemic in an unevidenced, heterogeneous
way and in conflict with relevant NICE guidance. Further research is needed urgently that assesses
the impact of this change on antibiotic prescribing and patient safety.
Keywords: antibiotic; stewardship; COVID-19; procalcitonin
1. Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread as
a global pandemic since late 2019. As of 8th February 2021, over 100 million cases and
almost 2.5 million deaths related to COVID-19 have been reported globally [1]. Around
one-fifth of infections result in severe disease [2] and in the UK, over 400,000 people have
been hospitalized with COVID-19 [3].
Although SARS-CoV-2 is a virus, patients hospitalised with COVID-19 frequently
receive empiric antibiotics to treat suspected or possible bacterial infection [4]. In the
case of influenza, bacterial infection occurs in 11% to 35% of patients, typically involves
S. aureus or S. pneumoniae and is associated with greatly increased mortality [5,6]. Over
time, evidence has accrued that bacterial infection during acute COVID-19 is less common,
estimated at <10% [7,8]. For COVID-19 patients with the most severe disease, bacterial
infection is a diagnosis to be excluded and empiric antibiotics are recommended based on
clinical judgement [9,10]. C-reactive protein (CRP) which, in other settings, is widely used
as a biomarker of bacterial infection, appears to reflect severity of illness and prognosis in
COVID-19, irrespective of the presence of additional bacterial infection [11].
Procalcitonin (PCT) is a polypeptide which has been investigated as a biomarker of
bacterial infection since a landmark paper published in 1993 reported the ability of PCT
to discriminate bacterial from viral infection [12]. While the performance characteristics
of PCT are superior to CRP in distinguishing bacterial from viral infection [13], the role
of measuring PCT in antimicrobial stewardship (AMS) is contentious. PCT assays are
approved for sepsis and respiratory tract infections by the US Federal Drug Administration,
but in the UK, current guidance from the National Institute for Health and Care Excellence
(NICE) does not include PCT testing, on the basis of insufficient evidence [14,15]. During
the first wave of COVID-19, anecdotal reports suggested some NHS acute hospitals had
introduced or expanded use of PCT testing to address concerns about antibiotic overuse in
COVID-19 patients. This was despite NICE rapid COVID-19 guidance NG173 advising
against routine PCT testing to guide antibiotic prescribing decisions [9].
The Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients
(PEACH) study [16] has been commissioned and funded by the National Institute of Health
Research (NIHR) to evaluate whether the use of PCT testing to guide antibiotic prescribing
safely reduced antibiotic use among patients admitted to acute UK NHS hospitals with
COVID-19. Here, we describe how acute NHS hospitals used PCT testing to guide antibiotic
prescribing during the first wave of the COVID-19 pandemic in England and Wales.
2. Results
Responses were received from 148 of 151 (98%) acute hospitals in England and Wales
comprising: East of England—16; London—19; Midlands—19; North East and Yorkshire—21;
North West—21; South East—17; South West—17; Wales—18.
Figure 1 shows the change in PCT use during the course of the first wave of the
COVID-19 pandemic. Prior to March 2020, PCT was in use for AMS at 70/147 hospitals in
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ICU (47.6%) and by 17 (11.6%) hospitals in the Emergency Department (ED)/Acute Medical
Unit (AMU). Of note, no hospital was using PCT in ED/AMU prior to the COVID-19
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Figure 1. Changed use of PCT testing at acute NHS hospitals in England and Wales. (A) Weekly number of hospi-
tals using procalcitonin (PCT) on intensive care unit (ICU) (-•-) and Emergency Department (ED)/Acute Medical Unit
(AMU) (-•-). For reference, the time course of the COVID-19 pandemic first wave in England is shown as weekly num-
ber of PCR positive cases (-). NG173 = National Institute for Health and Care Excellence (NICE) COVID-19 rapid
guideline NG173: [9] Data extracted from Public Health England (PHE) national COVID surveillance reports avail-
able at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/916994
/COVID19_Weekly_Report_09_September_2020.pdf (accessed on 21 February 2021). (B). Breakdown of changes in PCT use
on ICU and ED/AMU at 148 hospitals over the course of the pandemic first wave.
Many hospitals adopted PCT during the first wave of COVID-19 (Figure 1A); 57/146
(39.0%) of ED/AMUs and 54/147 (36.7%) of ICUs. Most introduced testing in late March
and early April as case numbers were increasing rapidly, and well before the publication
of NICE rapid guidance NG173 on 1st May 2020. By the end of June 2020, the number of
hospitals using PCT on ICU had increased to 124 (84.4% of hospitals) and use in ED/AMU
had quadrupled to 74 (50.7% of hospitals), with a further 10 hospitals planning to introduce
PCT into ED/AMU after wave 1 (Figure 1B). The discrepancy between the numbers of
clinical areas adopting PCT in Graph 1A and 1B is due to missing or inconsistent dates
provided by respondents.
In total, 116 respondents completed questions about PCT cut-offs in the ICU, and
78 in non-ICU settings, with most respondents reporting defined cut-offs for stopping or
withholding antibacterials in ICU, 107/116 (92.2%), and non-ICU, 68/78 (87.2%) settings
(Table 1). The most common cut-off value used on ICU was 0.5 ng/L (54/107 (50.5%)
hospitals specifying a level), while outside ICU, 0.25 ng/L was specified at the majority of
hospitals (41/68 (60.3%)). Twelve hospitals specified different cut-offs for ICU and non-ICU
patients: in 9, the ICU cut-off was higher, and in 3 the non-ICU cut-off was higher. Only
a minority of hospitals used PCT results without suggesting a threshold for stopping or
withholding antibiotics (9/116 (7.8%) in ICU and 10/78 (12.8%) non-ICU settings.
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Table 1. Nature of procalcitonin (PCT) use to support antibiotic prescribing during first wave of
COVID-19 pandemic in England and Wales.
ICU Non-ICU
PCT cut-off (ng/L) n = 116 n = 78
0.1 1(1%) 0
0.2 1 (1%) 0
0.25 51 (44%) 41 (53%)
0.5 54 (47%) 27 (35%)
No cut off specified, cut-off varied dependent on clinical context 9 (8%) 10 (13%)
Timing of PCT testing n = 114 n = 76
Single measurement 14 (12%) 39 (51%)
Two measurements 23 (20%) 21 (28%)
Serial 72 (63%) 9 (12%)
Other (i.e., varied dependent on clinical context) 5 (4%) 7 (9%)
PCT part of biochemistry order set n = 122 n = 107
Yes 50 (41%) 33 (31%)
Hospital guideline n = 114
PCT part of a Hospital guideline for managing COVID-19 55 (48%)
In total, 114 respondents completed questions about frequency of PCT testing in ICU
and 76 in non-ICU settings. Outside ICU, practice around how often to measure PCT
was fairly evenly split between taking a single measurement and taking two or serial
measurements. On ICU, taking two or more measurements was the norm (Table 1).
Less than half of hospitals, 50/122 (41.0%), using PCT in ICU had it as part of a
biochemistry order set and about a third had PCT as part of a biochemistry order set
outside ICU (33/107 (30.8%)). Similarly, around a half (55/114 (48.2%)) of hospitals had a
guideline for PCT use in AMS.
Perceptions of the Value of PCT and Future Plans
One hundred and fourteen respondents completed questions about perceived value
of PCT. The majority of respondents reported that they thought PCT had a positive effect
on controlling antibiotic overuse in COVID-19 patients with 78/114 (68.4%) responding
with either “Yes somewhat” or “Yes very much”. Twelve out of 114 (10.5%) gave a negative
response and thought PCT was “Probably not” or “Not at all” helpful in controlling antibi-
otic use and 24/114 (21.1%) were unsure. We explored the relationship between perceived
value of PCT testing and how the test was introduced (Figure 2). More respondents felt
the test was very useful if used with a cut-off of 0.5 ng/L and as part of an order set,
particularly in the ED/AMU setting.
The polar plot shows the percentage of respondents who felt PCT testing had been
either very useful, somewhat useful, were not sure or not/probably not useful according
to whether PCT had been used at their trust pre-COVID, within a guideline, as part of an
order set, with a high cut-off (0.5 ng/L) and as non-single use (two or serial measurements)
in the ICU or AMU/ED setting.
The majority of ICUs (104/111 (93.7%) that reported PCT use during the first COVID-19
wave plan to continue to use PCT for AMS post COVID. A smaller proportion using PCT in
ED and AMU report their intention to continue using PCT in those areas post COVID-19 for
AMS; 45/75 (60%) and 60/83 (72.3%), respectively.
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l i the COVID-19 pandemic, it was established that a raised CRP, which is widely
used as a biomarker of bacterial infection i the UK, reflected severity of illn ss rather than
bact rial superinfection in COVID-19 patients [17]. While the great majority of COVID-19
patients admitted to hospital in the UK during the first wave received antibiotics, a living
meta-analysis of data on the incidence of bacterial infection in patients with COVID-19
demonstrated that <1 in 20 COVID-19 patients had ‘bacterial co-infection’ at presentation
(4.9% (95% CI 2.6–7.1)), while 1 in 6 developed ‘secondary bacterial infection’ during their
hospital stay (16.0% (95% CI 12.4–19.6)) [18]. Around half the hospitals using PCT in
ED/AMU patients used a single test approach and half used two or serial testing, implying
a dichotomy of views about how best to use PCT to discontinue antibiotics.
Recognising the potential impact of COVID-19 on antibiotic prescribing, NICE pub-
lished a COVID-19 rapid guideline (NG173) to assist antibiotic prescribing decisions for
pneumonia in hospitalised adults, which recommended basing decisions to start antibiotics
on clinical judgement, radiographic changes and neutrophil count [9]. While acknowledg-
ing that PCT testing could be used, and encouraging centres using PCT to participate in
research, the guidance concluded “there is insufficient evidence to recommend routine
procalcitonin testing to guide decisions about antibiotics”. Our data indicate that this
guidance was produced after most hospitals had already adopted PCT testing, that most
of these hospitals plan to continue to use PCT testing to manage patients with COVID-19
and many hospitals plan to continue to use PCT for AMS post COVID-19, despite being
contrary to NICE guidance. We are aware of three UK hospitals who have since published
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details of their use of PCT to guide antibiotic use in COVID-19 [19–21]; these were all
retrospective cohort studies, suggesting that antibiotics could be safely withheld with a
PCT of <0.25 ng/L, but all findings are limited by uncontrolled confounders. Despite
a considerable body of research, the role of PCT as a tool to guide antibiotic prescrib-
ing decisions was contentious even prior to the COVID-19 pandemic. The most recent
systematic review and meta-analysis relevant to respiratory tract infection considered
6708 participants in 26 randomised controlled trials and concluded that use of PCT to guide
initiation and duration of antibiotic treatment resulted in lower risk of mortality, lower
antibiotic consumption and fewer antibiotic-related side effects [22]. Nevertheless, while
current Infectious Diseases Society of America (IDSA) antimicrobial stewardship guidance
supports use of PCT for antibiotic discontinuation decisions in critical care patients [23],
neither IDSA nor NICE recommend use of PCT to withhold antibiotics in patients with
community acquired pneumonia [9,24]. NICE Diagnostic Guideline DG18 on the use of
procalcitonin published in October 2015 concluded there to be insufficient evidence to
recommend that these tests are used in the NHS primarily because the PCT studies were
done in non-UK healthcare settings and the results, therefore, were not generalisable to
a UK healthcare setting [14,15]. NICE have since commissioned three UK PCT studies to
address the uncertainty of the efficacy of PCT in a UK healthcare setting: ADAPT Sepsis
(adult sepsis in the ICU) [25], PRONTO (adult ED sepsis) [26] and BATCH (paediatric
sepsis) [27]. The study protocol for PRONTO has been amended in light of the COVID-19
pandemic to accommodate COVID-19 patients.
We were not able to restrict data entry to a single response per site, so where there
were multiple responses, we disregarded incomplete entries, and this may have introduced
bias into the data collection process. A strength of this study was the high response rate
and triangulation of different data sources in acute NHS hospitals. In spite of this, there
were some missing data and a small number of inconsistencies that could not be resolved.
Further work within the PEACH [16] study will seek evidence for any impact of PCT
testing on antibiotic use and patient outcomes. Nevertheless, by gathering data from
almost every acute hospital, we have been able to highlight that PCT testing has been
adopted very widely and heterogeneously in the NHS. This adoption has not yet been
supported by evidence whether, or how, to use PCT safely and effectively in the context
of COVID-19 infection. In 2016, the World Health Organisation published its Guidance
for Managing Ethical Issues in Infectious Diseases Outbreaks, building on experience in
previous Ebola and Coronavirus epidemics [28]. This highlighted the importance of clinical
trials to evaluate treatments of emerging infectious diseases and to limit off-license use only
to situations where trials were unavailable. The large UK platform COVID-19 treatment
trials such as RECOVERY [29] and PRINCIPLE [30] have successfully limited off-label
prescribing in COVID-19, while providing safe and effective platforms for evaluation of
treatment options. Our results highlight the need for a similar approach to the deployment
of diagnostics in COVID-19 and future pandemics.
4. Materials and Methods
A web-based survey was developed by the authors [31]. This sought information
about use of PCT for AMS purposes during the first wave of COVID-19 in England
and Wales. The survey gathered information about: PCT use prior to the pandemic,
whether PCT was adopted during the pandemic and if so, in which areas of the hospital
(ICU, ED, AMU), PCT cut-offs, the testing algorithm, whether PCT was part of a hospital
guideline or biochemistry order set, whether participants thought PCT was useful in
efforts to control antibiotic overuse and whether participants plan to use PCT as part
of their antibiotic stewardship program after the first COVID-19 wave. We defined the
first wave of COVID-19 as 1 March 2021 through 6 July 2021. The survey was piloted by
three hospital AMS leads, and refined. The usability and technical functionality of the
electronic questionnaire was tested by the study team before being distributed through
UK antimicrobial pharmacist networks by email, Whatsapp and the UK Clinical Pharmacy
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Network notice board in December 2020 [32]. The survey was voluntary but reminders were
sent weekly for three weeks. Outstanding responses were chased personally by members
of the study team in January 2021 and the survey closed to responses on 25 January 2021.
When more than one survey was submitted from a hospital, the survey containing the
greater number of completed fields was included. Any discordant answers were checked
with the submitting hospital before removing the duplicate survey. In reporting the survey,
we have used the CHERRIES checklist for reporting results of Internet E-Surveys [33].
Ethical approval for the PEACH study was provided by NHS Health Research Authority
HRA and Health and Care Research Wales reference 21/WM/0052.
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